October 8, 2020

Remdesivir for the Treatment of Covid-19 – Final Report

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Infusion of the antiviral drug remdesivir led to faster recovery time (median 10 vs. 15 days) and a non-significantly lower risk of death at 29 days (HR=0.73, 95% CI 0.52-1.03) in a randomized, placebo-controlled trial among patients hospitalized with COVID-19. Serious adverse events were reported in 131 of 532 (24.6%) patients in the remdesivir group and in 163 of 516 (31.6%) patients in the placebo group. [EDITORIAL NOTE: A preliminary version of this manuscript was summarized in the Lit Rep on May 26, 2020.]

Beigel et al. (October 8, 2020). Remdesivir for the Treatment of Covid-19 – Final Report. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2007764